

# THNR

## Amplify Weight Loss Drug & Treatment ETF



### WHAT IS THNR?

THNR provides access to global companies pioneering the GLP-1 weight loss market and the broader value chain. Brand names like Ozempic, Wegovy, Mounjaro, and Zepbound are commonplace, but their GLP-1 manufacturers can be less well-known. Check out the chart below to see how each holding is taking part in the GLP-1 market.

### HOLDINGS

COMPANY NAME	TICKER	CATEGORY	HQ	HOLDING DETAILS
Altimune Inc.	<b>ALT</b>	Drug Manufacturing	US	Phase 2 Pemvidutide ALT-801
Amgen Inc.	<b>AMGN</b>	Drug Manufacturing	US	Phase 2, Maridebar cafraglutide activates GLP-1 while blocking GIP. Goals include quicker weight loss, less frequent dosing and better weight maintenance
AstraZeneca PLC	<b>AZN</b>	Drug Manufacturing	GB	Phase 1, Acquired Eccogene's GLP-1 drug
Bachem Holding AG	<b>BANB</b>	Value Chain (Enabler)	CH	Generic liraglutide
Catalent Inc	<b>CTLT</b>	Value Chain (Enabler)	US	Novo is acquiring Catalent as contract drug manufacturer (CDMO) to expand its GLP-1 production capabilities. Catalent, a CDMO, is helping produce Wegovy.
Eli Lilly & Co.	<b>LLY</b>	Drug Manufacturing	US	Mounjaro/Zepbound/Trulicity (retatrutide/tirzepatide)
FUJIFILM Holdings Corp.	<b>4901</b>	Value Chain (Enabler)	JP	Novo hired FUJIFILM Diosynth Biotechnologies to fill Wegovy injection pens, also testing via Wako Chemicals
Gerresheimer AG	<b>GXI</b>	Value Chain (Enabler)	DE	Makes injector pens for two key players
Merck & Co., Inc	<b>MRK</b>	Drug Manufacturing	US	Phase 2, efinopegdutide, developed as a treatment for non-alcoholic steatohepatitis (NASH), also showed a "compelling" weight-loss benefit.
Merck KGaA	<b>MRK GR</b>	Value Chain (Enabler)	DE	Merck KGaA's MilliporeSigma division provides life science research for GLP-1 drugs
Mitsubishi Chemical Group Corp.	<b>4188</b>	Drug Manufacturing	JP	Eli Lilly Japan and Mitsubishi Tanabe Pharma Corporation signed a sales collaboration agreement in Japan for GIP/GLP-1 receptor agonist "Tirzepatide"
Novo Nordisk A/S	<b>NOVO B</b>	Drug Manufacturing	DK	Ozempic/Wegovy/Rybelsus (semaglutide/liraglutide)
OPKO Health, Inc.	<b>OPK</b>	Drug Manufacturing	US	Phase 2 Oxyntomodulin
Pfizer Inc.	<b>PFE</b>	Drug Manufacturing	US	Phase 2 oral GLP-1 drug in pipeline (Danuglipron)
Roche Holdings AG	<b>ROG</b>	Drug Manufacturing	CH	Acquired Carmot Therapeutics GLP-1 drug Phase 1 CT388
Thermo Fisher Scientific Inc.	<b>TMO</b>	Value Chain (Enabler)	US	Novo hired Thermo Fisher as a contract manufacturer for Wegovy injection pens
Viking Therapeutics Inc.	<b>VKTX</b>	Drug Manufacturing	US	Oral/subcut drug in phase 1, VK2735 in phase 2
West Pharmaceutical Services	<b>WST</b>	Value Chain (Enabler)	US	Contract-manufacturer for GLP-1 drug injection
Ypsomed Holding AG	<b>YPSN</b>	Value Chain (Enabler)	CH	Autoinjector pen
Zealand Pharma A/S	<b>ZEAL</b>	Drug Manufacturing	DK	Phase 3 Survodutide, approved GIP drug and amlyn agonist in phase 1

Holdings as of 6/7/24, and are subject to change. See [AmplifyETFs.com/THNR/](https://AmplifyETFs.com/THNR/) for top ten holdings.

# THNR

Amplify Weight Loss Drug  
& Treatment ETF

**TO LEARN MORE, VISIT:**  
**[AmplifyETFs.com/THNR/](https://AmplifyETFs.com/THNR/)**



Access a global equity portfolio of companies pioneering GLP-1 therapies and the broader supply chain to capitalize on demand.



Significant growth opportunity as the GLP-1 market is anticipated to grow from \$6 billion to \$130 billion by 2023.<sup>1</sup>



Due to increasing demand, pharmaceutical companies are accelerating production of GLP-1 therapies.

**Carefully consider the Fund's investment objectives, risks, charges, and expenses before investing. This and other information can be found in the Fund's statutory and summary prospectuses, which may be obtained at [AmplifyETFs.com](https://AmplifyETFs.com). Read the prospectus carefully before investing.**

Investing involves risk, including the possible loss of principal. There can be no assurance that the Fund's investment objectives will be achieved. The fund is new with limited operating history. Shares of any ETF are bought and sold at market price (not NAV), may trade at a discount or premium to NAV and are not individually redeemed from the Fund. The Fund invests in securities included in its Index regardless of

their investment merit and may experience tracking error: the differences in timing of trades, valuation, plus fees and expenses between fund and index.

A non-diversified fund and can invest a greater portion of its assets in securities of individual issuers which could cause greater fluctuations than a diversified fund. A narrowly focused portfolio concentrated in the pharmaceutical industry or healthcare sector, may exhibit higher volatility and be vulnerable to factors affecting them due to regulation, litigation, costs and competition. Small and/or mid-capitalization companies may be more vulnerable to adverse general market or economic developments. Securities issued by foreign companies present risks beyond those of securities of U.S. issuers.

Amplify Investments LLC serves as the investment adviser to the Fund. Penserra Capital Management LLC serves as the investment sub-adviser to the Fund. Amplify ETFs are distributed by Foreside Fund Services, LLC.

Eli Lilly & Co (15.62%), Novo Nordisk A/S (15.39%), AstraZeneca PLC (6.00%), FUJIFILM Holdings Corp (5.47%), Amgen Inc (5.47%), Merck KGaA (5.31%), PFIZER Inc (5.25%), Merck and Co Inc (5.12%), Catalent Inc (4.87%), Roche Holdings AG (4.77%) are the top ten holdings in the THNR ETF as of 6/7/24.

<sup>1</sup><https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate>

**Not FDIC Insured | No Bank Guarantee | May Lose Value**